pharma
Commented by Fabian Lorenz on November 13th, 2026 | 05:41 CET
Singulus shares +1,500% thanks to Elon Musk! What are Almonty and Bayer doing?
Singulus shares have gained more than 1,500% this year. One major reason the machinery manufacturer has gone from a bankruptcy candidate to a high-flyer is Elon Musk. The first major order from his space company, SpaceX, has been placed, and analysts expect more. Almonty shares were also among the year's high-flyers until April. Since then, the stock has corrected sharply. This could offer investors an attractive opportunity to buy or add to their holdings. Analysts expect the tungsten producer to generate earnings of USD 2.76 per share next year. The shares are currently trading just above USD 8. Bayer shares are at a multi-year high. Analysts have raised the price target.
Read
Commented by Fabian Lorenz on November 6th, 2026 | 05:31 CET
BASF Keeps Up the Pressure on Evonik! Novo Nordisk Makes a Comeback! Is Strategic Resources Next?
A 25% share price gain and a year-high for BASF shares. The increase in the purchase price for Evonik cannot dampen investors' buying appetite. While the Ludwigshafen-based company is not letting up on Evonik, it is divesting parts of the group. Strategic Resources shares are a candidate for a comeback. To reduce CO₂ emissions, the steel industry is turning to electric arc furnaces. This threatens to cause shortages of high-quality iron ore pellets. Strategic Resources plans to supply these in the future. The shares have recently fallen sharply and offer an enticing entry point. At Novo Nordisk, the comeback is already under way. After a challenging year with profit warnings and a massive share price slump, there is finally positive news again. For a change, the full-year guidance was raised, not lowered. What do analysts say?
Read
Commented by Mario Hose on February 27th, 2026 | 07:05 CET
Revolution in cancer therapy: Vidac Pharma attacks the cancer throne of the big players! Why the smaller competitor could steal the show from giants like Bayer and BioNTech!
The world of biotechnology and pharmaceuticals is currently in turmoil, as technological breakthroughs and strategic realignments promise an exciting future for investors. The focus is particularly on Vidac Pharma, an innovative company that wants to revolutionize the fight against cancer with a completely new approach to oncology and is currently celebrating one milestone after another. While Vidac Pharma shines with impressive clinical progress and strong internal backing from its main shareholder, Dr. Max Herzberg, industry giant Bayer has recently struggled with the late effects of the Monsanto acquisition, but is now increasingly being touted as an exciting candidate for a split or takeover by financial investors. At the same time, BioNTech remains synonymous with cutting-edge mRNA technology, with the market eagerly awaiting the next phase after the pandemic. In this dynamic environment, Vidac Pharma is emerging as a particularly bright star in the biopharmaceutical sky, causing a sensation with its unique method of specifically normalizing the metabolism of cancer cells.
Read
Commented by André Will-Laudien on May 31st, 2022 | 12:03 CEST
Watch out: BioNTech, NervGen, MorphoSys, Valneva: Biotech shares in check!
The initial sell-off in biotech stocks seems to have been digested. With last week's NASDAQ turn, spring air is now moving through the stock markets again. That is because many investors realize that, in the face of a multitude of new diseases, a major research effort is needed to protect humanity from the burgeoning dangers. Financing via the stock market was correspondingly easy for the biotech giants during the last pandemic because investors sensed big profits in the event of success. This picture is likely to repeat itself in the next movement. Where are the current opportunities in the biopharma sector?
Read